Phase I/II trial of outpatient PEG-INTRON® with interleukin-2 (IL-2) in advanced renal cell carcinoma (RCC), a cytokine working group study

被引：0
|
作者：
Mehrabi, J
Atkins, M
Sosman, J
Logan, T
Margolin, K
Dutcher, J
Urba, W
Lau-Schwabe, A
Clark, J
机构：
[1] Loyola Univ, Maywood, IL 60153 USA
[2] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[3] Vanderbilt Univ, Nashville, TN USA
[4] Indiana Univ, Indianapolis, IN 46204 USA
[5] City Hope Natl Med Ctr, Duarte, CA 91010 USA
[6] Our Lady Mercy Med Ctr, Bronx, NY USA
[7] Providence Portland Med Ctr, Portland, OR USA
来源：
JOURNAL OF IMMUNOTHERAPY | 2004年 / 27卷 / 06期
关键词：
D O I：
10.1097/00002371-200411000-00068
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S18 / S18
页数：1
相关论文
共 50 条
  • [31] Phase III, randomized, multicentre trial of maintenance biotherapy with interleukin-2 (IL-2) and interferon-alpha (IFN) for metastatic renal cell cancer (RCC)
    Passalacqu, R
    Buzio, C
    Dalla Chiesa, M
    Camisa, R
    Porta, C
    Labianca, R
    Frassoldati, A
    Buti, S
    Pezzuolo, D
    Tomasello, G
    Caminiti, C
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 404S - 404S
  • [32] A phase II study of interleukin-2 with and without beta-interferon in the treatment of advanced renal cell carcinoma
    Witte, RS
    Leong, T
    Ernstoff, MS
    Krigel, RL
    Oken, MM
    Harris, J
    Tormey, DC
    Trump, DL
    INVESTIGATIONAL NEW DRUGS, 1995, 13 (03) : 241 - 247
  • [33] A phase II study of interferon α and low-dose subcutaneous interleukin-2 in advanced renal cell carcinoma
    A. Piga
    Paolo Giordani
    Agata Quattrone
    Marco Giulioni
    Giorgio De Signoribus
    Stefania Antognoli
    Riccardo Cellerino
    Cancer Immunology, Immunotherapy, 1997, 44 : 348 - 351
  • [34] A phase II trial of dose-intensive interleukin-2 in metastatic renal cell carcinoma
    Leslie Oleksowicz
    Janice P. Dutcher
    Journal of Cancer Research and Clinical Oncology, 1999, 125 : 101 - 108
  • [35] A phase II trial of dose-intensive interleukin-2 in metastatic renal cell carcinoma
    Oleksowicz, L
    Dutcher, JP
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1999, 125 (02) : 101 - 108
  • [36] Interleukin-2, interferon-α and interleukin-2 plus interferon-α in renal cell carcinoma.: A randomized phase II trial
    Boccardo, F
    Rubagotti, A
    Canobbio, L
    Galligioni, E
    Sorio, R
    Lucenti, A
    Cognetti, F
    Ruggeri, E
    Landonio, G
    Baiocchi, C
    Besana, C
    Citterio, G
    De Rosa, M
    Calabresi, F
    TUMORI, 1998, 84 (05) : 534 - 539
  • [37] Pharmacokinetics (PK) and immunologic responses in a phase I/II study of a sustained release formulation of IL-2 in renal cell carcinoma (RCC) patients.
    Oudard, S.
    Thiounn, N.
    Fridman, H.
    Amsellem-Ouazana, D.
    Colombel, M.
    Jacqmin, D.
    Malavaud, B.
    Kravtzoff, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 114S - 114S
  • [38] IMMUNOLOGICAL CHANGES IN PATIENTS WITH CANCER GIVEN INTERLEUKIN-2 (IL-2) IN A PHASE-I TRIAL
    LOTZE, MT
    FRANA, LW
    SEIPP, CA
    SHARROW, SO
    ROSENBERG, SA
    SURGICAL FORUM, 1984, 35 : 407 - 408
  • [39] A phase II study of bevacizumab (B) and high-dose aldesleukin (IL-2) in patients (p) with metastatic renal cell carcinoma (mRCC): A Cytokine Working Group Study (CWGS)
    Dandamudi, U. B.
    Ghebremichael, M. S.
    Sosman, J. A.
    Regan, M. M.
    Atkins, M. B.
    Clark, J.
    Dutcher, J. P.
    Curti, B. D.
    Vaishampayan, U. N.
    Ernstoff, M. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [40] PHASE-II STUDY OF SUBCUTANEOUS INTERLEUKIN-2 IN UNSELECTED PATIENTS WITH ADVANCED RENAL-CELL CANCER ON AN OUTPATIENT BASIS
    SLEIJFER, DT
    JANSSEN, RAJ
    BUTER, J
    DEVRIES, EGE
    WILLEMSE, PHB
    MULDER, NH
    JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (07) : 1119 - 1123
12345